clinical trial · NCT05243680
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
GlaxoSmithKline·phase3·completed·n = 641
AsthmaGSK3511294 (Depemokimab)
brief summary
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.
started
Mar 1, 2022
primary completion
May 19, 2025
completion
May 19, 2025
last updated
Jan 15, 2026
official title
A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol